Keyphrases
Advanced Colorectal Cancer
100%
Colorectal Cancer Patients
100%
Microsatellite Stable
100%
Epigenetic Modulators
100%
Pembrolizumab
100%
MK-3475
100%
Epigenetics
66%
Tumor
33%
Anemia
33%
Overall Survival
33%
Treatment-related
33%
Partial Response
33%
Thrombocytopenia
33%
Histone Deacetylases
33%
Tumor Growth
33%
Nausea
33%
Vomiting
33%
Anorexia
33%
Median Progression-free Survival
33%
DNA Methyltransferase 1 (DNMT1)
33%
Tumor Microenvironment
33%
Histone Deacetylase Inhibitor (HDACi)
33%
Lymphopenia
33%
DNA Methyltransferase Inhibitor
33%
Hematological Adverse Events
33%
Inhibit Tumor
33%
5-azacytidine
33%
Mismatch Repair
33%
Checkpoint Inhibitors
33%
Immune Infiltration
33%
PD-1 Immune Checkpoint Inhibitor
33%
Biological Endpoints
33%
Mechanistic Investigation
33%
PD-1 Blockade
33%
Immune Checkpoint Therapy
33%
RECIST Criteria
33%
Romidepsin
33%
Immune Checkpoint Inhibitor Therapy
33%
Biochemistry, Genetics and Molecular Biology
Microsatellite DNA
100%
Epigenetics
100%
Pembrolizumab
100%
DNA Methyltransferase
66%
Immune Checkpoints
66%
DNA Mismatch Repair
33%
Overall Survival
33%
Histone Deacetylase
33%
Tumor Progression
33%
Preclinical Study
33%
Progression Free Survival
33%
Immunocompetent Cell
33%
Histone Deacetylases Inhibitor
33%
Thrombocytopenia
33%
Azacitidine
33%
Cell Infiltration
33%
Romidepsin
33%
Medicine and Dentistry
Colorectal Cancer
100%
Pembrolizumab
100%
Arm
50%
DNA Methyltransferase
50%
Histone Deacetylase
50%
Neoplasm
25%
Anemia
25%
Lymphocytopenia
25%
Adverse Event
25%
Tumor Progression
25%
Nausea
25%
Overall Survival
25%
DNA Mismatch Repair
25%
Tumor Microenvironment
25%
Progression Free Survival
25%
Thrombocytopenia
25%
Anorexia
25%
Azacitidine
25%
Immune Cell Infiltration
25%
Immune Checkpoint Inhibitor
25%
Romidepsin
25%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Cancer
100%
Pembrolizumab
100%
Histone Deacetylase
50%
DNA Methyltransferase
50%
Neoplasm
25%
Adverse Event
25%
Anemia
25%
Lymphocytopenia
25%
Overall Survival
25%
Preclinical Study
25%
Thrombocytopenia
25%
Nausea
25%
Progression Free Survival
25%
Tumor Growth
25%
Anorexia
25%
Tumor Microenvironment
25%
Azacitidine
25%
Immune Checkpoint Inhibitor
25%
Romidepsin
25%